FUND+
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact. Fund+ was established in 2015 and is based in Leuven, Belgium.
FUND+
Founded:
2015-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Nginx
Similar Organizations
1315 Capital
1315 Capital provides expansion and growth capital to commercial stage pharmaceuticals, medical technologies, and healthcare services.
Section 32
Section 32 is a venture capital fund that invests at the cutting edge of technology, healthcare, and life sciences.
Susquehanna Growth Equity
Susquehanna Growth Equity invests in growth stage technology companies in the software, information services, and internet.
Winton Ventures
Winton Ventures invests in companies operating in the cybersecurity; energy and environment; and data science-driven healthcare sectors.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-25 | AstriVax | Fund+ investment in Seed Round - AstriVax | 30 M EUR |
| 2022-08-23 | eTheRNA immunotherapies | Fund+ investment in Series B - eTheRNA immunotherapies | 39 M EUR |
| 2022-05-31 | Minoryx Therapeutics | Fund+ investment in Series C - Minoryx Therapeutics | 51 M EUR |
| 2022-05-03 | Tubulis | Fund+ investment in Series B - Tubulis | 60 M EUR |
| 2022-02-19 | TargED Biopharmaceuticals | Fund+ investment in Series A - TargED Biopharmaceuticals | 39 M EUR |
| 2021-12-24 | EyeD Pharma | Fund+ investment in Venture Round - EyeD Pharma | 45 M EUR |
| 2021-10-28 | Novadip Biosciences | Fund+ investment in Series B - Novadip Biosciences | 19 M EUR |
| 2021-10-22 | Egle Therapeutics | Fund+ investment in Series A - Egle Therapeutics | 40 M EUR |
| 2021-08-25 | Cardior Pharmaceuticals | Fund+ investment in Series B - Cardior Pharmaceuticals | 64 M EUR |
| 2020-07-28 | ExeVir Bio | Fund+ investment in Series A - ExeVir Bio | 42 M EUR |
More informations about "Fund+"
ADC Manufacturing - Chain Link Fence Manufacturers Institute
ADC Manufacturing is the only domestic supplier of both aluminum and pressed steel fittings to the US fence industry today. Whether you’re looking for galvanized, aluminum, or powder …See details»
ChemExpress-Your Reliable Global CRO & CDMO Partner
ChemExpress focus on providing small molecule, new modalities and CDMO services for global pharmaceutical and biotech industry. We are committed to building a one-stop CRO&CDMO …See details»
MilliporeSigma Invests $76 Million to Expand ADC Manufacturing …
Oct 29, 2024 MilliporeSigma invests $76 million to triple its antibody-drug conjugate (ADC) manufacturing capacity and upgrade 34,000 sq ft at its BioConjugation Center of Excellence in …See details»
ADC manufacturing - Axplora
Looking for an ADC manufacturing partner? Axplora offers a full range of CDMO services for Antibody Drug Conjugates.See details»
Catalog - ADC Manufacturing
Make ADC Manufacturing your first choice for aluminum, galvanized and color fence fittings. We carry the largest selection of color inventory in the industry.See details»
Antibody Drug Conjugate Manufacturing | ADC Manufacturing
Antibody Drug Conjugate Manufacturing: Clinical to Commercial Services We offer clinical to commercial ADC manufacturing expertise and development services across all the ADC …See details»
ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing …
Jul 18, 2025 ADCs on the rise: MilliporeSigma, Lonza invest in manufacturing while BioNTech adds CMOs ahead of FDA filing There has been a rise in deals and investment to grow US …See details»
Process Development and Manufacturing of Antibody-Drug Conjugates
Jan 1, 2018 Antibody-drug conjugates (ADCs) are an emerging class of therapeutic that harnesses the binding specificity of an antibody to deliver a highly potent drug. There is …See details»
NJ Bio, Inc. — ADC Services
ADC services encompass the complete range of processes and expertise required for the successful development of ADCs from antibody production and bioconjugation to method …See details»
Antibody Drug Conjugate Services | ADC Manufacturing
Delivering excellence in antibody drug conjugate services with expertise in ADC development, bioconjugation, GMP manufacturing, and clinical batch production.See details»
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing …
With a unique and complex structure, there is inherent heterogeneity introduced by product-related variations and the manufacturing process. Here this review primarily covers recent key …See details»
ADC Manufacturing - Harrison Chamber of Commerce
ADC Manufacturing has over 4 decades of experience engineering and manufacturing products of consistent quality and providing customers exceptional service with competitive pricing. We …See details»
Your Guide To Producing ADCs That Meet cGMP Expectations
Aug 1, 2022 Antibody-drug conjugates (ADCs) are a diverse class of biopharmaceuticals that combine highly selective monoclonal antibodies specific to surface antigens present on …See details»
Antibody Drug Conjugates | ADC Contract Manufacturing | CMO
Outsourcing of development (eg. clinical development) and contract manufacturing services for ADCs (ADC clinical and commercial manufacturing) is common, owing to the complexity of …See details»
MilliporeSigma Invests $76 Million to Expand ADC Manufacturing …
Oct 29, 2024 MilliporeSigma Invests $76 Million to Expand ADC Manufacturing for Novel Cancer Therapies MilliporeSigma today announced a € 70 million expansion of its ADC manufacturing …See details»
Antibody–Drug Conjugate Manufacturing Challenges
Sep 19, 2023 Analytical as well as logistical challenges arise when as many as five separate CDMOs are engaged to complete GMP manufacturing of an ADC. With the recent uptick in …See details»
Antibody-drug Conjugates: Manufacturing Challenges and Trends
Jan 15, 2019 ADC manufacturing presents an exciting challenge to the industry. Progress is dependent not only upon innovative research in medicinal chemistries and biologics, but also …See details»
MilliporeSigma Invests $76 Million to Expand ADC Manufacturing …
St. Louis, Missouri, October 29, 2024 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of …See details»
CMC Regulatory Considerations for Antibody-Drug Conjugates
Through knowledge management and process understanding, changes in the ADC manufacturing processes can be adequately addressed and managed. Not all changes in early …See details»
Good Manufacturing Practice Strategy for Antibody–Drug …
To begin, a foundational approach based on a good manufacturing practice (GMP) strategy was used to adapt traditional ADC GMP production for site-specific ADC production. Using this …See details»